Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

117.65 -4.28 (-3.51%)
Official Closing Price Updated: 7:00 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
News headline image
FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority Review
From Merck & Co., Inc.
Via Business Wire
News headline image
European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma
From Merck & Co., Inc.
Via Business Wire
News headline image
European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Completes Acquisition of Acceleron Pharma Inc.
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1
From Merck & Co., Inc.
Via Business Wire
News headline image
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck and Ridgeback to Present Phase 3 Data for Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, at American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting
From Merck & Co., Inc.
Via Business Wire
News headline image
We're Training More Diverse Investigators to Help Improve Clinical Trials
SOURCE: Merck & Co., Inc. 
Via 3BL Media
News headline image
Seramount Names Merck As One of the 2021 Best Companies for Dads
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Topics Economy
News headline image
Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction Who Have Not Had a Recent Worsening Heart Failure Event
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, Upon Authorization or Approval
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck and Ridgeback Announce U.S. Government to Purchase 1.4 Million Additional Courses of Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults
From Merck & Co., Inc.
Via Business Wire
Global COVID-19 Therapeutics Market Size Now Expected To Exceed $25 Billion In 2030
Palm Beach, FL – November 9, 2021 – FinancialNewsMedia.com News Commentary – The increasing outbreak of covid-19 is increasing the demand for coronavirus vaccines or therapies, which will result in the... 
Via FinancialNewsMedia
Topics Death
News headline image
Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc.
From Merck & Co., Inc.
Via Business Wire
The $11 Trillion Healthcare Industry Is About To Change Forever
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 4, 2021 – The $11-trillion healthcare industry is going fully digital, disrupting industry giants & government... 
Via FinancialNewsMedia
News headline image
Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World
From Merck & Co., Inc.
Via Business Wire
News headline image
The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Topics Intellectual Property Regulatory Compliance
Global Metastatic Cancer Treatment Market Size Is Forecasted To Reach $111.16 Million By 2027
Palm Beach, FL – November 3, 2021 – FinancialNewsMedia.com News Commentary – The metastatic cancer treatment systems market is observing high demand attributed to its increasing application in breast,... 
Via FinancialNewsMedia
News headline image
New Research for KEYTRUDA® (pembrolizumab) at Society for Melanoma Research (SMR) 2021 Congress Reinforces Merck’s Commitment to Patients With Melanoma Across Stages of Disease
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Announces Third-Quarter 2021 Financial Results
From Merck & Co., Inc.
Via Business Wire
News headline image
The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2021
From Merck & Co., Inc.
Via Business Wire
News headline image
Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck and Ridgeback Announce Initiation of a Rolling Review by the European Medicines Agency for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of COVID-19 in Adults
From Merck & Co., Inc.
Via Business Wire
News headline image
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.